COVID-19 Vaccines Work in People with Cancer: Study

Moderna’s, Pfizer’s, and Johnson & Johnson’s shots all offered protection against the virus regardless of cancer type, although slightly less so in people with blood cancer.

Written byMarcus A. Banks
| 4 min read
a man in a white t-shirt and face mask receives a bandage on his arm from a clinician wearing blue gloves and a plastic face shield

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

ABOVE: © ISTOCK.COM, ERGIN YALCIN

COVID-19 vaccines offer robust protection against SARS-CoV-2 infection in people with cancer, according to an article published online June 5 in Cancer Cell. Vaccine protection levels are generally better for people with solid cancers than for patients with cancers of the blood, the researchers report, although most people with any cancer made detectable antibodies to the coronavirus after receiving a vaccine. Patients receiving treatments that suppressed the activity of their immune system, such as B cell–depleting therapies for leukemia, produced fewer antibodies after receiving a vaccine than did recipients with solid cancer.

Earlier this year, oncologists reported that COVID-19 is deadlier for people with blood cancer than it is for people with solid tumors. This was before vaccine uptake was widespread in the United States. The authors of the current study suggest that almost all people with cancer would benefit from vaccination, perhaps coupled with ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • marcus a. banks

    Marcus is a science and health journalist based in New York City. He graduated from the Science Health and Environmental Reporting Program at New York University in 2019, and earned a master’s in Library and Information Science from Dominican University in 2002. He’s written for Slate, Undark, Spectrum, and Cancer Today.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies